These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 11019384)
1. [Antipseudomonal activity of carbapenem antibiotics]. Sunagawa M; Kanazawa K; Nouda H Jpn J Antibiot; 2000 Jul; 53(7):479-511. PubMed ID: 11019384 [TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of carbapenems to the antagonism of the antipseudomonal activity of other beta-lactam agents and to the beta-lactamase inducibility in Pseudomonas aeruginosa: effects of 1beta-methyl group and C-2 side chain. Kanazawa K; Nouda H; Sumita Y; Sunagawa M J Antibiot (Tokyo); 1999 Feb; 52(2):142-9. PubMed ID: 10344568 [TBL] [Abstract][Full Text] [Related]
3. The mode of action of 2-(thiazol-2-ylthio)-1beta-methylcarbapenems against Pseudomonas aeruginosa: the impact of outer membrane permeability and the contribution of MexAB-OprM efflux system. Eguchi K; Ueda Y; Kanazawa K; Sunagawa M; Gotoh N J Antibiot (Tokyo); 2007 Feb; 60(2):129-35. PubMed ID: 17420563 [TBL] [Abstract][Full Text] [Related]
4. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2. Fung-Tomc JC; Gradelski E; Kolek B; Minassian B; Pucci M; Kessler RE; Bonner DP Antimicrob Agents Chemother; 1995 Feb; 39(2):386-93. PubMed ID: 7726503 [TBL] [Abstract][Full Text] [Related]
5. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Eagye KJ; Nicolau DP Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-beta-methyl carbapenem. Hazumi N; Fuse A; Matsuda K; Hashizume T; Sanada M Antimicrob Agents Chemother; 1995 Mar; 39(3):702-6. PubMed ID: 7793876 [TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp. Mohanty S; Maurya V; Gaind R; Deb M J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048 [TBL] [Abstract][Full Text] [Related]
10. Molecular typing and resistance mechanisms of carbapenem resistant Pseudomonas aeruginosa isolated from a Chinese surgical intensive care unit. Yi M; Wang P; Liu Y Chin Med J (Engl); 2014; 127(6):1071-6. PubMed ID: 24622437 [TBL] [Abstract][Full Text] [Related]
12. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia. McDougall DA; Morton AP; Playford EG J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714 [TBL] [Abstract][Full Text] [Related]
13. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea. Cho HH; Kwon GC; Kim S; Koo SH J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338 [TBL] [Abstract][Full Text] [Related]
15. [The Prevalence of Metallo-β-Lactamases and Efflux-Mediated Mechanisms in Carbapenem Nonsusceptible Nosocomial Pseudomonas aeruginosa Isolated in Moscow in 2012-2015]. Vestn Ross Akad Med Nauk; 2015; (6):679-83. PubMed ID: 27093795 [TBL] [Abstract][Full Text] [Related]
16. Transient carbapenem resistance induced by salicylate in Pseudomonas aeruginosa associated with suppression of outer membrane protein D2 synthesis. Sumita Y; Fukasawa M Antimicrob Agents Chemother; 1993 Dec; 37(12):2743-6. PubMed ID: 8109947 [TBL] [Abstract][Full Text] [Related]
17. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767 [TBL] [Abstract][Full Text] [Related]
19. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients. Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143 [TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]